Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study
The combination of ICIs and AAs showed favorable clinical benefits, safety and tolerability in uHCC patients with CP B cirrhosis, with some patients experiencing improvements in Child-Pugh score. More well-designed studies with larger sample sizes are warranted to further determine the efficacy and safety of systemic therapy in this population.
Authors
- Zirong Yang
- Sujun Zheng
- Wei Hou (ORCID: https://orcid.org/0000-0001-9223-424X)
- Lina Ma
- Dan Liu (ORCID: https://orcid.org/0000-0002-2198-3910)
- Junfeng Lu (ORCID: https://orcid.org/0000-0003-0558-6816)
- Shan Ren (ORCID: https://orcid.org/0000-0001-9668-8249)
- Lilin Wang (ORCID: https://orcid.org/0009-0000-5411-0545)
Institutions
- Weifang Medical University (CN)
- Beijing YouAn Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1186/s12885-025-15126-4
- Citations
- 1
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Capital Medical University